Get the Stockscreener App
1.66
4.08%
0.065
Pre-market:
1.69
0.03
+1.81%
Caribou Biosciences Inc stock is traded at $1.66, with a volume of 1.69M.
It is up +4.08% in the last 24 hours and down -22.43% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
See More
Previous Close:
$1.595
Open:
$1.61
24h Volume:
1.69M
Relative Volume:
1.12
Market Cap:
$164.64M
Revenue:
$11.16M
Net Income/Loss:
$-148.13M
P/E Ratio:
-1.045
EPS:
-1.5885
Net Cash Flow:
$-112.35M
1W Performance:
-9.78%
1M Performance:
-22.43%
6M Performance:
-2.92%
1Y Performance:
+49.55%
1-Day Range:
$1.61
$1.69
1-Week Range:
$1.59
$1.92
52-Week Range:
$1.04
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.66 | 164.64M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026 - Traders Union
Caribou Biosciences (CRBU) Slides 3.92%, Nears Critical Support at $1.51Catalyst Driven Stocks - newsline.com
Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA - Traders Union
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 - Investing News Network
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association Annual Meeting - Investing News Network
Caribou reports phase 1 trial data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou reports phase 1 data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou reports phase 1 data for off-the-shelf CAR-T therapy By Investing.com - Investing.com Australia
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results - TipRanks
CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update - Traders Union
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences (CRBU) reports durable phase 1 CAR-T responses in lymphoma and myeloma - Stock Titan
Off-the-shelf lymphoma cell therapy shows 82% response in early trial - Stock Titan
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears - Yahoo Finance
Caribou Biosciences (CRBU) Declines 7% as Key Support Level ApproachesVolatility Smirk - newsline.com
Caribou Biosciences advances CRISPR-based CAR-T... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Caribou Biosciences | DEFA14A: Others - Moomoo
CRBU Technical Analysis | Trend, Signals & Chart Patterns | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
CRBU DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class ActionCRBU - TMX Newsfile
Analyst Raises Caribou Biosciences Price Target Following Strong Results - asatunews.co.id
H.C. Wainwright Raises Caribou Biosciences Stock Price Target to $11 - HarianBasis.co
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows - Yahoo Finance
Caribou Biosciences (CRBU) Edges Higher as Stock Tests Key Resistance LevelsBPI Reversal - newsline.com
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Caribou Biosciences prepares to attend Jefferies Global Healthcare Conference in New York - Traders Union
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11 - Moomoo
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CRBU: Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials - TradingView
Caribou Biosciences stock (US1420381089): Q1 update and CRISPR pipeline stay in focus - AD HOC NEWS
CRBU Technical Analysis & Stock Price Forecast - Intellectia AI
Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat - Traders Union
Caribou Biosciences stock (US1420381089): fresh data from latest CAR?T update keeps investors watchi - AD HOC NEWS
Transcript : Caribou Biosciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 08 - marketscreener.com
Caribou Biosciences (CRBU) price target increased by 38.57% to 12.37 - MSN
Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surge - AD HOC NEWS
May 2026's Promising Penny Stocks - Yahoo Finance
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU) - The Globe and Mail
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference - Investing News Network
Caribou Biosciences attends BioConnect Investor Conference in New York next week - Traders Union
CRISPR biotech Caribou Biosciences plans H.C. Wainwright talk May 19 - Stock Titan
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues - simplywall.st
Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 30% - Moomoo
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts - Yahoo Finance
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association Annual Meeting - Investing News Network
EHA2026 spotlights Caribou Biosciences advances in allogeneic CAR-T treatments for lymphoma and multiple myeloma - Traders Union
Caribou Biosciences, Inc. Announces Acceptance of Two Oral Presentations at the 2026 European Hematology Association Annual Meeting - Quiver Quantitative
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences CEO Rachel Haurwitz to join Bank of America conference fireside chat - Traders Union
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):